NCT00699114

Brief Summary

The purpose of this placebo controlled clinical trial is to evaluate the dose response relationship of ibuprofen in doses from 400 mg to 800 mg and paracetamol (acetaminophen)in doses from 500 mg to 1000 mg compared with paracetamol (acetaminophen)1000 mg plus codeine 60 mg on acute postoperative pain after surgical removal of impacted third molars.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
350

participants targeted

Target at P75+ for phase_4 surgery

Timeline
Completed

Started Jun 2007

Typical duration for phase_4 surgery

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2007

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

June 12, 2008

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 17, 2008

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2009

Completed
Last Updated

July 6, 2011

Status Verified

February 1, 2009

Enrollment Period

2.5 years

First QC Date

June 12, 2008

Last Update Submit

July 3, 2011

Conditions

Keywords

PainAnalgesicsMolarThirdAcetaminophenParacetamolIbuprofenCodeinePlacebo

Outcome Measures

Primary Outcomes (1)

  • Sum Pain Intensity Score(SPI)

    3 hour observation period

Secondary Outcomes (7)

  • Sum Pain Intensity Difference Score (SPID)

    3 hours

  • Sum Pain Intensity Score (SPI)

    6 hours

  • Sum Pain Intensity Difference Score (SPID)

    6 hours

  • Maximum Pain Intensity Difference Score (MAXPID)

    Unknown, calculated variable

  • Time to Maximum Pain Intensity Difference Score

    Unknown, calculated variable

  • +2 more secondary outcomes

Study Arms (7)

Placebo

PLACEBO COMPARATOR

Single dose placebo capsule

Drug: Placebo

Ibuprofen 400 mg

ACTIVE COMPARATOR

Single dose ibuprofen 400 mg capsule

Drug: Ibuprofen 400 mg

Ibuprofen 600 mg

ACTIVE COMPARATOR

Single dose ibuprofen 600 mg capsule

Drug: Ibuprofen 600 mg

Ibuprofen 800 mg

ACTIVE COMPARATOR

Single dose ibuprofen 800 mg capsule

Drug: Ibuprofen 800 mg

Paracetamol 500 mg

ACTIVE COMPARATOR

Paracetamol 500 mg (acetaminophen) capsule

Drug: Paracetamol (acetaminophen) 500 mg

Paracetamol 1000 mg

ACTIVE COMPARATOR

Single dose paracetamol 1000 mg (acetaminophen) capsule

Drug: Paracetamol (acetaminophen) 1000 mg

Paracetamol 1000 mg + codeine 60 mg

ACTIVE COMPARATOR

Single dose paracetamol (acetaminophen) 1000 mg + codeine 60 mg capsule

Drug: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg

Interventions

Lactose as powder in gelatine capsules, single dose

Also known as: Lactose
Placebo

Ibuprofen 400 mg as powder in gelatine capsules, single dose

Also known as: M01A E01 Ibuprofen
Ibuprofen 400 mg

Ibuprofen 600 mg as powder in gelatine capsules, single dose

Also known as: M01A E01 Ibuprofen
Ibuprofen 600 mg

Ibuprofen 800 mg as powder in gelatine capsules, single dose

Also known as: M01A E01 Ibuprofen
Ibuprofen 800 mg

Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose

Also known as: N02B E01 Paracetamol (acetaminophen)
Paracetamol 500 mg

Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose

Also known as: N02B E01 Paracetamol (acetaminophen)
Paracetamol 1000 mg

Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose

Also known as: N02B E01 Paracetamol (acetaminophen) + R05D A04 codeine
Paracetamol 1000 mg + codeine 60 mg

Eligibility Criteria

Age18 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patients of both sexes referred for surgical removal of impacted third molars, due to symptoms or after being advised to do so by their dentist.
  • Persons of both sexes (ASA type I).
  • Females who are not pregnant or plan conception.
  • Persons who have not used analgesics for 3 days prior to the day of surgery.
  • Persons without known active ulcus or gastrointestinal bleeding.
  • Persons without any known hypersensitivity for NSAIDs.
  • Persons under no other continuous drug treatment than contraceptives.
  • Caucasian origin.
  • Persons with at least moderate postoperative pain as defined by subjective score on a verbal rating scale after surgical removal of third molars.

You may not qualify if:

  • Patients with surgery time exceeding 60 minutes
  • Peroperative complications such as profuse bleeding or perforation to the maxillary sinus requiring additional drug treatment during or after the surgical removal of the third molar.
  • Postoperative complications such as extended bleeding, nausea and regurgitation during the observation period.
  • Smoking before taking the test-drug or during the observation period.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital

Oslo, N-0407, Norway

Location

Related Publications (1)

  • Lyngstad G, Skjelbred P, Swanson DM, Skoglund LA. Analgesic effect of oral ibuprofen 400, 600, and 800 mg; paracetamol 500 and 1000 mg; and paracetamol 1000 mg plus 60 mg codeine in acute postoperative pain: a single-dose, randomized, placebo-controlled, and double-blind study. Eur J Clin Pharmacol. 2021 Dec;77(12):1843-1852. doi: 10.1007/s00228-021-03231-9. Epub 2021 Oct 16.

MeSH Terms

Conditions

Pain

Interventions

LactoseIbuprofenAcetaminophenCodeine

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

DisaccharidesOligosaccharidesPolysaccharidesCarbohydratesSugarsPhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAcetanilidesAnilidesAmidesAniline CompoundsAminesMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Study Officials

  • Lasse A Skoglund, DDS, DSCi

    Section of Dental Pharmacology and Pharmacotherapy, ICD, Faculty of Dentistry, University of Oslo, POB 1119 Blindern, N-0317 Oslo, Norway

    STUDY CHAIR
  • Per Skjelbred, MD, DDS, PhD

    Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital, Kirkeveien 166, N-0407 Oslo, Norway

    STUDY DIRECTOR
  • Gaute Lyngstad, DDS

    Section of Dental Pharmacology and Pharmacotherapy, ICD, Faculty of Dentistry, University of Oslo, POB 1119 Blindern, N0317 Oslo, Norway

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 12, 2008

First Posted

June 17, 2008

Study Start

June 1, 2007

Primary Completion

December 1, 2009

Study Completion

December 1, 2009

Last Updated

July 6, 2011

Record last verified: 2009-02

Locations